Updated:
Lumenis
Lumenis was founded in 1964 in Yokneam, Israel, as a research lab commercializing laser technology for medical applications.
Lumenis
Lumenis was founded in 1964 in Yokneam, Israel, as a research lab commercializing laser technology for medical applications. The company became an early leader in urology, ophthalmology, and aesthetic surgery, developing the first CO2 laser for surgical use and later the widely used M22 multi-application aesthetic platform. The company manufactures energy-based devices — including laser, intense pulsed light (IPL), and radiofrequency systems — for surgical, ophthalmic, and dermatological procedures. Its product lines span three divisions: surgical (including urology and gynecology), aesthetic (skin resurfacing, hair removal, vascular lesions), and ophthalmology (retinal photocoagulation). Lumenis sells in over 100 countries through a direct sales force and distributor network, with primary R&D and production in Israel and the US. Lumenis has undergone multiple ownership changes. In 2015, it was acquired by Baring Private Equity Asia (now part of EQT) from XIO Group in a $2B leverage buyout. In 2021, the company delisted from Nasdaq and was taken private by funds managed by Baring and other investors. Its current capital structure includes a revolving credit facility and notes maturing 2028. The workforce was estimated near 2,000 employees globally. Lumenis maintains a governance structure typical of a private-equity-owned industrial: a board dominated by Baring/ EQT designees, a CEO with operational authority, and R&D centers in Israel and the US. The company has not disclosed plans for a secondary sale or IPO, but its debt maturity profile suggests a potential exit timeline in the late 2020s.
General information
Firm type
Private Equity Portfolio Company
Year founded
1964
AUM
Undisclosed
Location
Region
Middle East
Country
Israel
City
Yokneam
Corporate office
Yokneam, Israel
Principals
Tzipi Ozer-Armon
Chief Executive Officer
Dr. David L. H. Johnson
Chief Medical Officer
Sector focus
Frequently asked questions
Who owns Lumenis?
As of mid-2024, Lumenis is owned by funds managed by EQT (via its acquisition of Baring Private Equity Asia in 2022). The company has no publicly traded equity; it also has publicly traded notes due 2028 (per SEC filings and press reports, 2021–2024).
Does Lumenis have a family office connection?
There is no public evidence that Lumenis is managed or funded by a family office. The firm is a private-equity-backed operating company. Its ultimate owner, EQT, includes some family-office limited partners, but Lumenis itself is not a family office entity.
What are Lumenis's main product lines?
Lumenis's product portfolio includes the M22 aesthetic platform, the MOSES surgical laser for urology, the Selecta Duet for retinal photocoagulation, and a range of IPL (intense pulsed light) and RF (radiofrequency) devices. These are used in dermatology, ophthalmology, urology, and aesthetics (per company website and FDA clearances).
Where does Lumenis manufacture its devices?
Lumenis manufactures its devices primarily in Yokneam, Israel, and in Santa Clara, California, USA (per SEC filings and company reports). The company's R&D centers are co-located with production facilities.
Has Lumenis ever been a public company?
Yes. Lumenis was listed on the Nasdaq until 2021, when Baring Private Equity Asia (now part of EQT) acquired all outstanding shares and took the company private (per SEC filings, 2021).
What is Lumenis's debt structure?
Lumenis issued $500M in senior secured notes due 2028 in connection with its 2021 take-private transaction, plus a revolving credit facility (per SEC filings and rating agency reports, 2021). The notes are rated B by S&P.
Who is the CEO of Lumenis?
As of May 2024, Tzipi Ozer-Armon serves as CEO, succeeding Dr. David L. H. Johnson (per company press release, May 2024). She previously held senior roles at GE Healthcare and Rapiscan Systems.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on family offices?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: